These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17048064)

  • 1. Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study.
    Häussler B; Gothe H; Göl D; Glaeske G; Pientka L; Felsenberg D
    Osteoporos Int; 2007 Jan; 18(1):77-84. PubMed ID: 17048064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis in German men: a cost-of-illness study.
    Berghaus S; Müller D; Gandjour A; Civello D; Stock S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):531-7. PubMed ID: 25495596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden-of-illness study on osteoporosis in the Slovenian female population.
    Dzajkovska B; Wertheimer AI; Mrhar A
    Pharm World Sci; 2007 Aug; 29(4):404-11. PubMed ID: 17310302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost of fractures in German hospitals--what role does osteoporosis play?].
    Bleibler F; Benzinger P; Lehnert T; Becker C; König HH
    Gesundheitswesen; 2014 Mar; 76(3):163-8. PubMed ID: 23709102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013.
    Wang CY; Fu SH; Yang RS; Shen LJ; Wu FL; Hsiao FY
    Arch Osteoporos; 2017 Oct; 12(1):92. PubMed ID: 29067572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland.
    Lippuner K; Golder M; Greiner R
    Osteoporos Int; 2005 Mar; 16 Suppl 2():S8-S17. PubMed ID: 15378232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.
    Ray NF; Chan JK; Thamer M; Melton LJ
    J Bone Miner Res; 1997 Jan; 12(1):24-35. PubMed ID: 9240722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient costs of osteoporosis in a national health insurance population.
    Krappweis J; Rentsch A; Schwarz UI; Krobot KJ; Kirch W
    Clin Ther; 1999 Nov; 21(11):2001-14. PubMed ID: 10890269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic aspects of osteoporosis].
    Stĕpán J; Smíd M; Prokes M; Palicka V; Honzáková L; Havelka S; Blahos J; Bayer M
    Cas Lek Cesk; 1998 Nov; 137(23):707-15. PubMed ID: 9990174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical costs of osteoporosis in the elderly Medicare population.
    Blume SW; Curtis JR
    Osteoporos Int; 2011 Jun; 22(6):1835-44. PubMed ID: 21165602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model.
    Bleibler F; Rapp K; Jaensch A; Becker C; König HH
    BMC Health Serv Res; 2014 Jun; 14():284. PubMed ID: 24981316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology and costs of osteoporosis].
    Götte S; Dittmar K
    Orthopade; 2001 Jul; 30(7):402-4. PubMed ID: 11515176
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
    Mueller D; Gandjour A
    Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050.
    Konnopka A; Jerusel N; König HH
    Osteoporos Int; 2009 Jul; 20(7):1117-29. PubMed ID: 19048180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden of osteoporosis in California, 1998.
    Max W; Sinnot P; Kao C; Sung HY; Rice DP
    Osteoporos Int; 2002; 13(6):493-500. PubMed ID: 12107664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.